The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Temocapril     2-[(2S)-6-[[(1S)-1- ethoxycarbonyl-3-phenyl...

Synonyms: Temocaprilum, CHEMBL590800, AG-K-31053, SureCN1650365, AC-1131, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of temocapril hydrochloride


High impact information on temocapril hydrochloride

  • The survival time was significantly shortened (15.6+/-0.3 weeks) in the IGF-1 group but significantly prolonged (19.5+/-0.6 weeks) in the temocapril group [1].
  • The alpha-MHC mRNA level was decreased by 52% (p<0.01) in the IGF group, while it increased by 58% (p<0.01) in the temocapril group compared with the control group [1].
  • [Pro(11), D-Ala(12)]Ang I (10(-8) to 10(-5) mol/L), a chymase-specific substrate, provoked similar responses in rat and hamster arteries; chymostatin, but not temocapril, attenuated the responses [5].
  • First, we examined the effects of the ACE inhibitor temocapril and the angiotensin II AT1 subtype receptor antagonist CS-866 on the structural remodeling induced by administering L-NAME for 8 weeks [6].
  • In VSMC conditioned medium, FN-induced elevation of Ang II was significantly inhibited by temocapril but not by chymostatin [7].

Chemical compound and disease context of temocapril hydrochloride


Biological context of temocapril hydrochloride


Anatomical context of temocapril hydrochloride


Associations of temocapril hydrochloride with other chemical compounds


Gene context of temocapril hydrochloride


Analytical, diagnostic and therapeutic context of temocapril hydrochloride

  • Furthermore, high doses of CS-866 or temocapril treatment significantly reduced the positive stainings for transforming growth factor-beta (TGF-beta), vascular endothelial growth factor, and type IV collagen in glomeruli of diabetic rats [24].
  • Variation of SI during temocapril treatment did not reach statistical significance (0.95+/-0.2 before vs. 1.44+/-0.4 x 10(-4)/min/mU/L after treatment) [25].
  • Western blot showed that temocapril enhanced cytosolic redox regulatory protein TRX expression, but neither mitochondrial TRX2 nor antioxidant enzymes, such as copper-zinc superoxide dismutase (Cu/Zn-SOD) or manganese superoxide dismutase (Mn-SOD) expression, was increased by the preconditioning treatment [26].
  • Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning [27].
  • In a prospective randomised cross-over study, we compared the effects of ACE inhibitor temocapril and calcium channel blocker (CCB) amlodipine on ambulatory blood pressure in 59 asymptomatic elderly hypertensive patients (mean age 69 years) [28].


  1. Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction. Iwanaga, Y., Kihara, Y., Yoneda, T., Aoyama, T., Sasayama, S. J. Am. Coll. Cardiol. (2000) [Pubmed]
  2. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Oguchi, H., Miyasaka, M., Koiwai, T., Tokunaga, S., Hora, K., Sato, K., Yoshie, T., Shioya, H., Furuta, S. Clinical pharmacokinetics. (1993) [Pubmed]
  3. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Yuan, Z., Kishimoto, C., Shioji, K., Nakamura, H., Yodoi, J., Sasayama, S. Cardiovasc. Res. (2002) [Pubmed]
  4. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction. Sakata, Y., Yamamoto, K., Mano, T., Nishikawa, N., Yoshida, J., Miwa, T., Hori, M., Masuyama, T. Cardiovasc. Res. (2003) [Pubmed]
  5. Alternative angiotensin II formation in rat arteries occurs only at very high concentrations of angiotensin I. Inoue, K., Nishimura, H., Kubota, J., Kawamura, K. Hypertension (1999) [Pubmed]
  6. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Takemoto, M., Egashira, K., Tomita, H., Usui, M., Okamoto, H., Kitabatake, A., Shimokawa, H., Sueishi, K., Takeshita, A. Hypertension (1997) [Pubmed]
  7. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype. Hu, W.Y., Fukuda, N., Ikeda, Y., Suzuki, R., Tahira, Y., Takagi, H., Matsumoto, K., Kanmatsuse, K., Mugishima, H. J. Cell. Physiol. (2003) [Pubmed]
  8. Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. Yoshida, K., Kohzuki, M., Xu, H.L., Wu, X.M., Kamimoto, M., Sato, T. J. Hypertens. (2001) [Pubmed]
  9. Cardiac calcineurin during transition from hypertrophy to heart failure in rats. Hayashida, W., Kihara, Y., Yasaka, A., Sasayama, S. Biochem. Biophys. Res. Commun. (2000) [Pubmed]
  10. Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. Okuro, M., Morimoto, S., Takahashi, T., Okaishi, K., Nakahashi, T., Murai, H., Iwai, K., Kanda, T., Matsumoto, M. Hypertens. Res. (2006) [Pubmed]
  11. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Horita, Y., Tadokoro, M., Taura, K., Suyama, N., Taguchi, T., Miyazaki, M., Kohno, S. Hypertens. Res. (2004) [Pubmed]
  12. Evaluation of systemic blood NO dynamics by EPR spectroscopy: HbNO as an endogenous index of NO. Kirima, K., Tsuchiya, K., Sei, H., Hasegawa, T., Shikishima, M., Motobayashi, Y., Morita, K., Yoshizumi, M., Tamaki, T. Am. J. Physiol. Heart Circ. Physiol. (2003) [Pubmed]
  13. An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats. Nagashima, H., Uto, K., Sakomura, Y., Aoka, Y., Sakuta, A., Aomi, S., Hagiwara, N., Kawana, M., Kasanuki, H. J. Vasc. Surg. (2002) [Pubmed]
  14. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Imai, T., Imoto, M., Sakamoto, H., Hashimoto, M. Drug Metab. Dispos. (2005) [Pubmed]
  15. Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction? Sugie, T., Kagaya, Y., Takeda, M., Yahagi, H., Takahashi, C., Takahashi, J., Ninomiya, M., Watanabe, J., Ichinohasama, R., Tezuka, F., Shirato, K. Cardiovasc. Res. (2003) [Pubmed]
  16. Identification of di-(2-ethylhexyl) phthalate-induced carboxylesterase 1 in C57BL/6 mouse liver microsomes: purification, cDNA cloning, and baculovirus-mediated expression. Furihata, T., Hosokawa, M., Koyano, N., Nakamura, T., Satoh, T., Chiba, K. Drug Metab. Dispos. (2004) [Pubmed]
  17. Influence of temocapril on cultured ventral spinal cord neurons. Iwasaki, Y., Ichikawa, Y., Igarash, O., Ikeda, K., Kinoshita, M. Neurochem. Res. (2003) [Pubmed]
  18. Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats. Nozawa, M., Sugimoto, K., Ohmori, M., Ando, H., Fujimura, A. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  19. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha. Makino, T., Hattori, Y., Matsuda, N., Onozuka, H., Sakuma, I., Kitabatake, A. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  20. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. Zaman, A.K., Fujii, S., Goto, D., Furumoto, T., Mishima, T., Nakai, Y., Dong, J., Imagawa, S., Sobel, B.E., Kitabatake, A. J. Mol. Cell. Cardiol. (2004) [Pubmed]
  21. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Taniyama, Y., Morishita, R., Nakagami, H., Moriguchi, A., Sakonjo, H., Shokei-Kim, n.u.l.l., Matsumoto, K., Nakamura, T., Higaki, J., Ogihara, T. Circulation (2000) [Pubmed]
  22. Endothelial nitric oxide synthase-independent effects of an ACE inhibitor on coronary flow response to bradykinin in aged mice. Talukder, M.A., Fujiki, T., Morikawa, K., Motoishi, M., Matsuo, Y., Hatanaka, M., Tsutsui, M., Takeshita, A., Shimokawa, H. J. Cardiovasc. Pharmacol. (2004) [Pubmed]
  23. Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Rakugi, H., Okamura, A., Kamide, K., Ohishi, M., Sasamura, H., Morishita, R., Higaki, J., Ogihara, T. Hypertens. Res. (1997) [Pubmed]
  24. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Koga, K., Yamagishi, S., Takeuchi, M., Inagaki, Y., Amano, S., Okamoto, T., Saga, T., Makita, Z., Yoshizuka, M. Mol. Med. (2002) [Pubmed]
  25. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2. Lerch, M., Weidmann, P., Ho, M.P., Gerber, P., Eckenberger, P., Kaemmereit, A., Teuscher, A.U. J. Cardiovasc. Pharmacol. (1999) [Pubmed]
  26. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Yuan, Z., Kishimoto, C., Shioji, K., Nakamura, H., Yodoi, J., Sasayama, S. Mol. Cell. Biochem. (2003) [Pubmed]
  27. Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Nozawa, Y., Miura, T., Tsuchida, A., Kita, H., Fukuma, T., Shimamoto, K. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1999) [Pubmed]
  28. Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients. Eguchi, K., Kario, K., Shimada, K. Journal of human hypertension. (2001) [Pubmed]
WikiGenes - Universities